U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 21 - 30 of 11,247 results

Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (ABSOLUTE)



Lemborexant is a dual orexin receptor antagonist, which inhibits orexin by binding competitively to two subtypes of orexin receptors. During normal periods of sleep, orexin system activity is suppressed, suggesting it is possible to purposefully faci...
Status:
US Approved Rx (2018)
First approved in 2018

Class (Stereo):
CHEMICAL (ACHIRAL)



Doravirine (MK-1439) is a nonnucleoside inhibitor of HIV reverse transcriptase (NNRTI). It displays excellent activities against not only WT viruses but also a broader panel of NNRTI-resistant viruses. Doravirine is a prescription medicine approved b...
Status:
US Approved Rx (2018)
First approved in 2018

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cannabidiol is the major nonpsychoactive ingredient in cannabis. Cannabidiol demonstrates a range of effects that may be therapeutically useful, including anti-seizure, antioxidant, neuroprotective, anti-inflammatory, analgesic, anti-tumor, anti-psy...
Status:
US Approved Rx (2024)
First approved in 2018

Class (Stereo):
CHEMICAL (ABSOLUTE)



Tezacaftor (VX-661) is an investigational compound developed by Vertex Pharmaceuticals to treat cystic fibrosis (CF). It is an oral corrector of the CF transmembrane regulator (CFTR) and is similar to lumacaftor, another N-aryl-1-(2,2-difluoro-1,3-be...
Status:
US Approved Rx (2018)
First approved in 2018

Class (Stereo):
CHEMICAL (ACHIRAL)



Gilteritinib, also known as ASP2215, is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations. In in vitro, among the 78 tyrosine kinases tested, Gilteritinib inhibited...
Status:
US Approved Rx (2018)
First approved in 2018

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Stiripentol is an anticonvulsant drug used in the treatment of epilepsy. It recently proved to increase the GABAergic transmission in vitro in an experimental model of immature rat. Clinical studies were based on the fact that STP also acts as an inh...
Status:
US Approved Rx (2018)
First approved in 2018

Class (Stereo):
CHEMICAL (ACHIRAL)



Fostamatinib is a pro-drug of a Syk inhibitor R406 initially developed by Rigel Pharmaceuticals, but then in-licensed by AstraZeneca. It reached phase III of clinical trials for such diseases as Rheumatoid Arthritis and Immune Thrombocytopenic Purpur...
Status:
US Approved Rx (2021)
First approved in 2017

Class (Stereo):
CHEMICAL (ABSOLUTE)



Pibrentasvir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS5A inhibitor that targets the the viral RNA replication and viron assembly. NS5A is a phosphoprotein that plays an essential role in replication, assembly and maturation of...
Status:
US Approved Rx (2017)
First approved in 2017

Class (Stereo):
CHEMICAL (ACHIRAL)



Brigatinib (AP26113) is an investigational, targeted cancer medicine discovered internally at ARIAD Pharmaceuticals, Inc. Brigatinib has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor rec...
Status:
US Approved Rx (2017)
First approved in 2017

Class (Stereo):
CHEMICAL (ACHIRAL)



Ribociclib, also known as LEE011, is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. CDK4/6 inhibitor LEE011 specifically inhibits CDK...